Entera Bio
ENTX
10 hedge funds and large institutions have $6.54M invested in Entera Bio in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.12% less ownership
Funds ownership: 17.19% → 17.07% (-0.12%)
17% less funds holding
Funds holding: 12 → 10 (-2)
54% less capital invested
Capital invested by funds: $14.2M → $6.54M (-$7.67M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$65.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.33K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$5K |
| 4 |
Morgan Stanley
New York
|
-$4.87K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$511 |
ENTX Hedge Fund Activity: Q2 2022 in Review
10 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q2 2022, worth a combined $6.54M — down 54% from $14.2M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ENTX and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $6.1K. The largest seller was Millennium Management, cutting an estimated $65.2K.
- 10 institutional investors held Entera Bio (ENTX) as of Q2 2022, down from 12 in Q1 2022.
- Funds reported $6.54M of Entera Bio stock for Q2 2022, down 54% quarter-over-quarter.
- 0 funds opened new Entera Bio positions in Q2 2022 and 2 closed out, a net change of -2 holders.
- The largest Entera Bio buyer in Q2 2022 was UBS Group, an estimated $6.1K added.
- The largest Entera Bio seller in Q2 2022 was Millennium Management, an estimated $65.2K sold.
Based on aggregated 13F filings for Q2 2022.